Nikhil Palekar,* MD, Associate Professor of Psychiatry, Director of Geriatric Psychiatry, and Medical Director of the Center for Excellence for Alzheimer’s Disease at the Renaissance School of Medicine at Stony Brook University, is available to discuss the newly approved FDA treatment for Alzheimer’s disease called Adacunamab.
Dr. Palekar can address these issues with the drug and its potential to change treatment for some Alzheimer’s patients:
- This is the first disease modifying medication to be approved for Mild Cognitive Impairment due to Alzheimer’s disease (MCIa) and mild Alzheimer’s disease since 2003. It will provide another treatment option for patients struggling with this illness. Although the medication does not reverse or halt memory loss, it has shown to slow progression of the disease and improve functioning which would provide patients with more time…
